DNO ASA
19.1.2021 10:18:13 CET | Globenewswire | Press release
Oslo, 19 January 2021 – DNO ASA, the Norwegian oil and gas operator, today announced that its wholly-owned subsidiary DNO Norge AS has been awarded participation in 10 exploration licenses, of which 4 are operatorships, under Norway's Awards in Predefined Areas (APA) 2020 licensing round.
Of the 10 new licenses, six are in the North Sea and four in the Norwegian Sea. Prior to today's announcement, DNO held interests in 76 licenses offshore Norway, of which 19 are operated by the Company.
The new awards under the APA 2020 licensing round include:
PL836 SB: Wintershall DEA Norge AS (operator), Spirit Energy Norway AS, DNO Norge AS (30%)
PL1084: Lundin Energy Norway AS (operator), DNO Norge AS (40%)
PL1086: DNO Norge AS (operator, 50%), Petoro AS, Source Energy AS
PL1102: Lundin Energy Norway AS (operator), DNO Norge AS (40%)
PL1106: DNO Norge AS (operator, 40%), Petoro AS, Petrolia Noco AS, Lundin Energy Norway AS
PL1108: DNO Norge AS (operator, 40%), Pandion Energy AS, OKEA ASA
PL1109: OMV (Norge) AS (operator), ONE-Dyas Norge AS, DNO Norge AS (30%)
PL1112: A/S Norske Shell (operator), Neptune Energy Norge AS, Spirit Energy Norge AS, DNO Norge AS (20%)
PL1120: DNO Norge AS (operator, 40%), Equinor Energy AS, Vår Energy AS, Wintershall DEA Norge AS
PL1127: Equinor Energy AS (operator), Total E&P Norge AS, DNO Norge AS (20%)
–
For further information, please contact:
Media: media@dno.no
Investors: investor.relations@dno.no
–
DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands, Ireland and Yemen.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novartis Pharma AG29.3.2026 07:15:00 CEST | Press release
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
